SCHEMBL13078022

SCHEMBL13078022

C[C@@H](NCc1ccc(-c2ccccc2)s1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.55
HDAC4 P56524 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
CYP2C19 P33261 4/20 0.49
CYP3A4 P08684 3/20 0.49
CYP2A6 P11509 3/20 0.49
CYP2C9 P11712 3/20 0.49
CYP2E1 P05181 2/20 0.49
CYP2B6 P20813 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.46
CYP2D6 P10635 3/20 0.44
CASR P41180 3/20 0.44
CHRM2 P08172 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CHRM1 P11229 1/20 0.44
SMPD1 P17405 1/20 0.44
DRD1 P21728 1/20 0.44
TBXA2R P21731 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14469669 0.87 HTT (0.65) HTTHDAC4HDAC6CYP2C19CYP3A4
SCHEMBL13077975 0.80 CASR (0.50) HDAC4HDAC6CYP2C19CYP3A4CYP2A6
SCHEMBL14849575 0.80 CASR (0.50) HDAC4HDAC6CYP2C19CYP3A4CYP2A6
SCHEMBL2368653 0.76 PRKCI (0.69) CYP2C19CYP3A4CYP2A6CYP2C9CYP2E1
SCHEMBL13077954 0.74 HTT (0.57) HTTHDAC4HDAC6CYP2C19CYP3A4
SCHEMBL3739482 0.74 HTT (0.50) HTTHDAC4HDAC6CYP2C19CYP3A4
SCHEMBL12903062 0.73 CYP2A6 (0.55) CYP2C19CYP3A4CYP2A6CYP2C9CYP2E1
SCHEMBL13749525 0.73 CYP2A6 (0.58) CYP2C19CYP3A4CYP2A6CYP2C9CYP2E1
SCHEMBL20881276 0.73 PRKCI (0.55) CYP2C19CYP3A4CYP2A6CYP2C9CYP2E1
SCHEMBL1750017 0.71 SMN1; SMN2 (0.72) HTTCYP2C19CYP3A4SMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES LEO PHARMA A/S (DK) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279936-A1 SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES C1R, C3AR1, PTH1R HTT 3886/4885HDAC4 648/4885HDAC6 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.